New painkiller mirogabalin takes on diabetic nerve pain
NCT ID NCT07451431
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether mirogabalin can reduce nerve pain in people with diabetes. 78 adults will take either mirogabalin or the standard drug pregabalin daily for 8 weeks. Researchers will measure pain levels, side effects, and quality of life to see if mirogabalin is a better option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mirogabalin
- What this could lead to
- If it works, mirogabalin could offer a new option for managing diabetic nerve pain with possibly fewer side effects.
- What could go wrong
- This is a small, early-phase trial comparing to an existing drug, so results may not confirm superiority or long-term safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bangladesh Medical University
RECRUITINGDhaka, 1000, Bangladesh
More trials for these conditions
Other studies related to the condition(s) this trial covers.